Description
GW-501516 ( Cardarine) 15MG Pellets
ℹ️ What is GW-501516?
Developed in the 1990s by GlaxoSmithKline and Ligand Pharmaceuticals.
It is a selective agonist of the PPARδ receptor (Peroxisome Proliferator-Activated Receptor delta).
Often sold as a “research chemical”, sometimes abused in sports/bodybuilding for its effects on endurance and fat metabolism.
⚙️ Operation
Activates PPARδ → stimulates fat burning and increases endurance.
May lead to a shift in energy metabolism from glucose to fatty acids.
Considered by some to be “exercise mimetic” because it mimics effects of endurance training.
🧪 Usage & status
Never approved as medicine.
Clinical studies were discontinued after evidence in animal studies showed that GW-501516 may promote tumour growth.
Has been on the WADA doping list (banned in sport).
⚠️ Risks
Potential carcinogenic effects (seen in laboratory animals with prolonged use).
Unknown safety in humans, no official dose or approved application.
Usually used as research chemical sold → risk of impurity and wrong dosage.
🏷️ Product: GW-501516 - “Cardarine”
Shape: Powder, capsules or tablets (variable by provider)
Strength: Often offered in doses of 5-20 mg per capsule/tablet
Usage: Sold exclusively as a research chemical - not intended for consumption or medical use ⚠️📋 Features
Fabric type: Selective PPARδ agonist
Molecular formula: C₂₁H₁₈F₃NO₃S₂
Molecular weight: approx. 453.5 g/mol
CAS number: 317318-70-0
🔬 Application (research)
Used in research on fat metabolism, insulin sensitivity and endurance.
Known as “exercise mimetic” because it can mimic effects of endurance training.
⚠️ Important warning
Not approved as a medicine.
In animal studies associated with increased risk of tumours.
Banned since 2009 by WADA in sports.
Usually offered for laboratory research and not for human use.

